Hikma Triumphs As Vascepa Induced-Infringement Case Dismissed
Amarin Had Pursued Firm Over Skinny-Label Generic Icosapent Ethyl Capsules
Executive Summary
An attack on Hikma’s skinny-label generic version of Vascepa by originator Amarin, claiming induced infringement of patents protecting a cardiovascular indication, has been dismissed in the US.
You may also be interested in...
Hikma Warns Of Renewed Pricing Pressure On US Generics
Hikma has warned of renewed pressure on generics in the US after a “gradual worsening of the pricing environment” in 2021. However, the company still managed to achieve growth of a tenth in its generics segment last year, on the back of key launches.
Appeals Court Rehearing Rejected In Teva-GSK Skinny-Label Saga
Teva will not get a third hearing at the US Court of Appeals for the Federal Circuit in its long-running dispute with GSK over skinny-label generics, after the appeals court rejected a petition for the full bench to re-examine the case.
Does Hikma’s Vascepa Litigation Dismissal Suggest Safety For Skinny Labels?
An induced-infringement attack on Hikma’s skinny-label generic version of Vascepa had been cited as evidence of the potential harm that would be caused by controversial rulings in separate litigation involving GSK and Teva. However, these fears may now appear overstated after the claim against Hikma was dismissed.